Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩25,300, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩23,800, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩29,900, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Upcoming Dividend • May 19
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 26 May 2026. Payment date: 16 June 2026. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.9%). Valuation Update With 7 Day Price Move • May 12
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to ₩44,050, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years. Duyuru • May 07
Huons Global Co., Ltd. to Report Q1, 2026 Results on May 12, 2026 Huons Global Co., Ltd. announced that they will report Q1, 2026 results on May 12, 2026 New Risk • May 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (13% average weekly change). Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩63,200, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 220% over the past three years. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₩56,100, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 200% over the past three years. Upcoming Dividend • Mar 26
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 02 April 2026. Payment date: 23 April 2026. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%). Duyuru • Mar 17
Huons Global Co., Ltd., Annual General Meeting, Mar 31, 2026 Huons Global Co., Ltd., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩63,300, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 226% over the past three years. Duyuru • Feb 06
Huons Global Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026 Huons Global Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026 Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩48,750, the stock trades at a trailing P/E ratio of 36.6x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 180% over the past three years. Upcoming Dividend • Nov 17
Upcoming dividend of ₩550 per share Eligible shareholders must have bought the stock before 24 November 2025. Payment date: 12 December 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.7%). Lower than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 266% over the past three years. Duyuru • Nov 01
Huons Global Co., Ltd. to Report Q3, 2025 Results on Nov 10, 2025 Huons Global Co., Ltd. announced that they will report Q3, 2025 results on Nov 10, 2025 Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩58,500, the stock trades at a trailing P/E ratio of 43.9x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 261% over the past three years. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (2.0% net profit margin). New Risk • Aug 30
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Dividend is not well covered by cash flows (96% cash payout ratio). Upcoming Dividend • Aug 13
Upcoming dividend of ₩130 per share Eligible shareholders must have bought the stock before 20 August 2025. Payment date: 08 September 2025. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%). Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩48,400, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 124% over the past three years. Upcoming Dividend • Jun 20
Upcoming dividend of ₩275 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 25 August 2025. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%). Duyuru • Apr 23
Huons Global Co., Ltd. to Report Fiscal Year 2024 Final Results on May 02, 2025 Huons Global Co., Ltd. announced that they will report fiscal year 2024 final results at 3:30 PM, Korea Standard Time on May 02, 2025 Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩44,850, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 64% over the past three years. Duyuru • Apr 03
Huonslab Co., Ltd. Announces Significantly Enhanced Bioavailability of SC Infliximab Co-formulated with HyDIFFUZE™? in Sprague-Dawley Ratifies for Presentation At AACR 2025 Huonslab Co., Ltd. ("Huonslab"), a subsidiary of Huons Global announced that its abstract titled “The Role of HyDIFFUZE™ in Co-formulation with Subcutaneous Infliximab” has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place on April 28, 2025. The study demonstrated that HyDIFFUZE™ (rHuPH20) significantly improves the relative bioavailability of co-formulated infliximab compared to infliximab without rHuPH20 when administered subcutaneously. These findings suggest that co-formulation with HyDIFFUZE (rHuPH20) may reduce the required dose of infliximab while maintaining equivalent therapeutic efficacy and potentially extending dosing interval in the maintenance regimen. Huonslab previously validated the role of HyDIFFUZE™ (rHuPH20) as a locally acting, transient permeation enhancer for subcutaneous delivery of high-dose, high-volume biotherapeutics, supported by dye dispersion studies in nude mice and in vivo comparative pharmacokinetic (PK) studies in Sprague-Dawley rats. In parallel, Huonslab is currently conducting a pivotal Phase 1 clinical trial in South Korea for Hydizyme™, a stand-alone recombinant human hyaluronidase (rHuPH20) drug product, with the goal of obtaining product approval from the Ministry of Food and Drug Safety (MFDS) by 2026. New Risk • Mar 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.2% Last year net profit margin: 5.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (3.2% net profit margin). Duyuru • Mar 15
Huons Global Co., Ltd., Annual General Meeting, Mar 28, 2025 Huons Global Co., Ltd., Annual General Meeting, Mar 28, 2025, at 08:30 Korea Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩41,550, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years. New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (12% average weekly change). Buy Or Sell Opportunity • Dec 03
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 42% to ₩33,950. The fair value is estimated to be ₩27,274, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩41,700, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 12% over the past three years. New Risk • Nov 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change). Duyuru • Oct 26
Huons Global Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024 Huons Global Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024 New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩21,350, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 66% over the past three years. Duyuru • May 25
Huons Global Co., Ltd. (KOSDAQ:A084110) announces an Equity Buyback for KRW 2,000 million worth of its shares. Huons Global Co., Ltd. (KOSDAQ:A084110) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose behind the program is to improve shareholder value and to stabilize stock price. The program will expire on November 26, 2024. As of May 23, 2024, the company had 347,172 shares in treasury within scope available for dividend and had 26,245 shares in treasury through other repurchase. Upcoming Dividend • Mar 22
Upcoming dividend of ₩275 per share Eligible shareholders must have bought the stock before 29 March 2024. Payment date: 19 April 2024. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.5%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%). Duyuru • Mar 15
Huons Global Co., Ltd., Annual General Meeting, Mar 28, 2024 Huons Global Co., Ltd., Annual General Meeting, Mar 28, 2024, at 08:30 Korea Standard Time. Location: B1F, A-dong Pangyo I-Square, 17, Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do Gyeonggi-do South Korea Agenda: To Business report, audit report, and report on the current status of the internal accounting management system; to Approval of financial statements for the 37th term (Fiscal Year 2023); and to discuss other matters. Duyuru • Jan 31
Huons Global Co., Ltd. to Report Q4, 2023 Results on Feb 14, 2024 Huons Global Co., Ltd. announced that they will report Q4, 2023 results on Feb 14, 2024 Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩903 (vs ₩438 in 3Q 2022) Third quarter 2023 results: EPS: ₩903 (up from ₩438 in 3Q 2022). Revenue: ₩190.6b (up 14% from 3Q 2022). Net income: ₩11.1b (up 106% from 3Q 2022). Profit margin: 5.8% (up from 3.2% in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance. Duyuru • Oct 24
Huons Global Co., Ltd. to Report Q3, 2023 Results on Nov 07, 2023 Huons Global Co., Ltd. announced that they will report Q3, 2023 results on Nov 07, 2023 Duyuru • Aug 03
Huons Global Co., Ltd. to Report Q2, 2023 Results on Aug 08, 2023 Huons Global Co., Ltd. announced that they will report Q2, 2023 results on Aug 08, 2023 Upcoming Dividend • Dec 21
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Inside Director Wan-Sup Kim was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Inside Director Wan-Sup Kim was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 13% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩50,200, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 24% over the past three years. Reported Earnings • May 17
First quarter 2021 earnings released: EPS ₩617 (vs ₩580 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: ₩131.6b (up 13% from 1Q 2020). Net income: ₩7.31b (up 5.1% from 1Q 2020). Profit margin: 5.5% (down from 6.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 07
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩59,700, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 5.5% over the past three years. Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improved over the past week After last week's 65% share price gain to ₩61,200, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 15% share price gain to ₩35,750, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 44% over the past three years. Is New 90 Day High Low • Jan 29
New 90-day low: ₩26,550 The company is down 1.0% from its price of ₩26,762 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩400 Per Share Will be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 1.3% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.6%). Is New 90 Day High Low • Oct 26
New 90-day low: ₩29,050 The company is down 10.0% from its price of ₩32,350 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: ₩30,800 The company is down 7.0% from its price of ₩33,150 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 32% over the same period.